Psychiatr. pro Praxi, 2006; 1: 39-42

Venlafaxin s prodlouženým uvolňováním v ambulantní praxi

MUDr. Luboš Janů Ph.D
Psychiatrická klinika FN a LF UK v Plzni

Venlafaxin je duální antidepresivum s dobrou účinností a snášenlivostí u širokého spektra depresivních a úzkostných poruch. Tato látka může být účinná i u jiných diagnóz – somatoformní, premenstruální dysforické a posttraumatické stresové poruchy. Venlafaxin má potenciál k rychlejšímu nástupu antidepresivního působení a vyšší účinnost než SSRI, zejména u specifických skupin pacientů.

Keywords: Klíčová slova: venlafaxin, depresivní porucha, úzkostné poruchy.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janů L. Venlafaxin s prodlouženým uvolňováním v ambulantní praxi. Psychiatr. praxi. 2006;7(1):39-42.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Altamura AC, Pioli R, Vitto M, Mannu P: Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders. Int Clin Psychopharmacol. 1999 Jul;14(4):239-45. Go to original source... Go to PubMed...
    2. Benedictis E: Double-blind comparison of venlafaxine and amitriptyline in outpatients with major depression with or without melancholia. J Psychopharmacol. 2000 Mar;14(1):61-6. Go to original source... Go to PubMed...
    3. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T: Venlafaxine extended-release capsules in panic disorder: Flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry. 2005 Oct;187:352-9. Go to original source... Go to PubMed...
    4. Cohen L, Kornstein S, Entsuah, R, Ortega-Leon W, Meng MS, Roy-Byrne, Tummala R,: Age and gender diference inantidepressant treatment: A comparative analysis of venlafaxine, selective serotonin reuptake inhibitors. Poster presented at the American Collegue of Neuropsychopharmacology, San Juan, Puerto Rico, 2004.
    5. Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Yan B, Pedersen R, Musgung J: Treatment of posttraumatic stres disorder with venlafaxine XR: A 6-month randomized, controlled trial. Poster presented at the American Collegue of Neuropsychopharmacology, San Juan, Puberto Rico, 2004.
    6. Derivan A, Entsuah AR, Kikta D: Venlafaxine: measuring the onset of antidepressant action. Psychopharmacol Bull. 1995;31(2):439-47. Go to PubMed...
    7. Einarson TR, Arikian SR, Casciano J, Doyle JJ: Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther. 1999 Feb;21(2):296-308. Go to original source... Go to PubMed...
    8. Einarson A, Fatoye B, Sarkar M, Lavigne SV, Brochu J, Chambers C, Mastroiacovo P, Addis A, Matsui D, Schuler L, Einarson TR, Koren G: Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry. 2001 Oct;158(10):1728-30. Go to original source... Go to PubMed...
    9. Entsuah R, et al: Venlafaxine vs SSRI: Pooled remission analysis (Megaanalysis of 31 studies of more than 7000 patients. Poster presented at the American Collegue of Neuropsychopharmacology, San Juan, Puerto Rico, 2002.
    10. Fava M. Entsuah, R, Tummala R,: Comparison of venlafaxine, selective serotonin reuptake inhibitors and placebo in the treatment of patiens with anxious depression. Poster presented at the American Collegue of Neuropsychopharmacology, San Juan, Puerto Rico, 2004.
    11. Hollander E, Friedberg J, Wasserman S, Allen A, Birnbaum M, Koran LM: Venlafaxine in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2003 May;64(5):546-50. Go to original source... Go to PubMed...
    12. Kašparová L., Novotná H.: Pharmindex Brevíř 2005, MediMedia Information spol. s r.o., Praha 2005.
    13. Kent JM: SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet. 2000 Mar 11;355(9207):911-8. Review. Erratum in: Lancet 2000 Jun 3;355(9219):2000. Go to original source... Go to PubMed...
    14. Khan A, Upton GV, Rudolph RL, Entsuah R, Leventer SM: The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group. J Clin Psychopharmacol. 1998 Feb;18(1):19-25. Go to original source... Go to PubMed...
    15. Klamerus KJ, Parker VD, Rudolph RL, Derivan AT, Chiang ST: Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996 Sep-Oct;16(5):915-23. Go to PubMed...
    16. Kroenke K, Benattia I, Musgnung J, Graepel J, Stahl S: Short-term treatment of depressed and anxious primary care patiens with multiple, unexplained somatic symptoms: A pilot study. Poster presented at the Američan Collegue of Neuropsychopharmacology, San Juan, Puerto Rico, 2004. Go to original source...
    17. Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry. 2005 Feb;66(2):238-47. Go to original source... Go to PubMed...
    18. Liebowitz MR, Gelenberg AJ, Munjack: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry. 2005 Feb;62(2):190-8. Go to original source... Go to PubMed...
    19. Mahapatra SN, Hackett D: A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract. 1997 Jun;51(4):209-13. Go to original source... Go to PubMed...
    20. Mehtonen OP, Sogaard J, Roponen P, Behnke K: Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000 Feb;61(2):95-100. Go to original source... Go to PubMed...
    21. Mendels J, Johnston R, Mattes J, Riesenberg R: Efficacy and safety of b.i.d. doses of venlafaxine in a dose-response study. Psychopharmacol Bull. 1993;29(2):169-74. Go to PubMed...
    22. De Nayer A, Geerts S, Ruelens L, Schittecatte M, De Bleeker E, Van Eeckhoutte I, Evrard JL, Linkowski P, Fossion P, Leyman S, Mignon A: Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002 Jun;5(2):115-20. Go to original source... Go to PubMed...
    23. Poirier MF, Boyer P: Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison. Br J Psychiatry. 1999 Jul;175:12-6. Go to original source... Go to PubMed...
    24. Post RM, Altshuler LL, Frye MA, Suppes T, Rush AJ, Keck PE Jr, McElroy SL, Denicoff KD, Leverich GS, Kupka R, Nolen WA: Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers. Bipolar Disord. 2001 Oct;3(5):259-65. Go to original source... Go to PubMed...
    25. Rudolph RL, Entsuah R, Chitra R: A meta-analysis of the effects of venlafaxine on anxiety associated with depression. J Clin Psychopharmacol. 1998 Apr;18(2):136-44. Go to original source... Go to PubMed...
    26. Schweizer E, Feighner J, Mandos LA, Rickels K: Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry. 1994 Mar;55(3):104-8.
    27. Schmitt R, Gazalle FK, Lima MS, Cunha A, Souza J, Kapczinski F: The efficacy of antidepressants for generalized anxiety disorder: a systematic review and meta-analysis. Rev Bras Psiquiatr. 2005 Mar;27(1):18-24. Epub 2005 Apr 18. Go to original source... Go to PubMed...
    28. Thase ME, Entsuah AR, Rudolph R: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001 Mar;178:234-41. Go to original source... Go to PubMed...
    29. Thase ME, Entsuah, R, Ahmed S, Sloan DM, Nemeroff ChB: Meta- and funnle plot analyse of studies comparing venlafaxine and SSRI: The evidence revisited. Poster presented at the American Collegue of Neuropsychopharmacology, San Juan, Puerto Rico, 2004.
    30. Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F: Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia. Int Clin Psychopharmacol. 2000 Jan;15(1):29-34. Go to original source... Go to PubMed...
    31. Vieta E, Martinez-Aran A, Goikolea JM, Torrent C, Colom F, Benabarre A, Reinares M: A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002 Jun;63(6):508-12. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.